{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["50(3)"],"submitter":["Wang L"],"pubmed_abstract":["Serology tests for SARS-CoV-2 provide a paradigm for estimating the number of individuals who have had an infection in the past (including cases that are not detected by routine testing, which has varied over the course of the pandemic and between jurisdictions). Such estimation is challenging in cases for which we only have limited serological data and do not take into account the uncertainty of the serology test. In this work, we provide a joint Bayesian model to improve the estimation of the sero-prevalence (the proportion of the population with SARS-CoV-2 antibodies) through integrating multiple sources of data, priors on the sensitivity and specificity of the serological test, and an effective epidemiological dynamics model. We apply our model to the Greater Vancouver area, British Columbia, Canada, with data acquired during the pandemic from the end of January to May 2020. Our estimated sero-prevalence is consistent with previous literature but with a tighter credible interval."],"journal":["The Canadian journal of statistics = Revue canadienne de statistique"],"pagination":["734-750"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9538003"],"repository":["biostudies-literature"],"pubmed_title":["Estimation of SARS-CoV-2 antibody prevalence through serological uncertainty and daily incidence."],"pmcid":["PMC9538003"],"pubmed_authors":["Min J","Elliott LT","Colijn C","Doig R","Wang L"],"additional_accession":[]},"is_claimable":false,"name":"Estimation of SARS-CoV-2 antibody prevalence through serological uncertainty and daily incidence.","description":"Serology tests for SARS-CoV-2 provide a paradigm for estimating the number of individuals who have had an infection in the past (including cases that are not detected by routine testing, which has varied over the course of the pandemic and between jurisdictions). Such estimation is challenging in cases for which we only have limited serological data and do not take into account the uncertainty of the serology test. In this work, we provide a joint Bayesian model to improve the estimation of the sero-prevalence (the proportion of the population with SARS-CoV-2 antibodies) through integrating multiple sources of data, priors on the sensitivity and specificity of the serological test, and an effective epidemiological dynamics model. We apply our model to the Greater Vancouver area, British Columbia, Canada, with data acquired during the pandemic from the end of January to May 2020. Our estimated sero-prevalence is consistent with previous literature but with a tighter credible interval.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2025-04-19T06:44:15.836Z","creation":"2025-04-19T06:44:15.836Z"},"accession":"S-EPMC9538003","cross_references":{"pubmed":["36248322"],"doi":["10.1002/cjs.11722"]}}